Data Sheet (Cat.No.T22611)

TargetMol

BMS 961

Chemical Properties



CAS No. : 185629-22-5

Formula: C23H26FNO4

Molecular Weight: 399.46

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BMS961 is a potent and selective retinoic acid receptor gamma (RARγ) agonist (IC50: 30 nM).
Targets(IC50)	Others,Retinoid Receptor
In vitro	In vitro, the application of BMS961on mouse ear skin was found to cause a significant increase of thymic stromal lymphopoietin (TSLP) transcripts1. In addition, exposure of BMS861 on limbs at low concentration leads to retarded growth of the zeugopod (long bones) and intactness of autopod (paw). However, a high concentration of BMS961treatment caused equal undifferentiation of both limb regions 2.
In vivo	In WT mice, RARγ agonists BMS961treatment resulted in an increase of the ear TSLP transcripts and serum TSLP, which indicates an involvement of RAR-mediated events in transcriptional activation of TSLP expression1.

Solubility Information

Solubility	DMSO: <39.95 mg/mL,Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5034 mL	12.5169 mL	25.0338 mL
5 mM	0.5007 mL	2.5034 mL	5.0068 mL
10 mM	0.2503 mL	1.2517 mL	2.5034 mL
50 mM	0.0501 mL	0.2503 mL	0.5007 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Gavai AV, Fink BE, Fairfax DJ, et al. Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J Med Chem, 2009, 52(21): 6527-6530.

Wong TW, Lee FY, Yu C, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res, 2006, 12(20 Pt 1): 6186-6193.